October 1, 2019 - The INVENT Network has formally endorsed the COBRRA Trial: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism - an open-label RCT (randomized controlled trial) comparing bleeding risk with rivaroxaban versus apixaban for acute treatment of VTE (venous thromboembolism).
The COBRRA Trial is an investigator-initiated trial led by Dr. Lana Castellucci (Principal Investigator) . The trial began recruiting in late 2017 and is currently recruiting at 15 sites in Canada and set to open new sites in Australia.
The endorsement of the COBRRA Trial marks the 15th study / trial endorsed by the network since its inception in 2016.